The closing removes completion risk and solidifies the balance sheet. With extended runway into Q2 2028, the company has increased financial flexibility to execute on its cardiovascular gene therapy pipeline. Monitor for upcoming clinical catalysts and potential business development activities enabled by this liquidity.
Price Chart
Executive Summary
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.
Key Facts
- Completed sale of PRV for $180.0 million in gross proceeds
- Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
- Cash runway extended into Q2 2028
- Transaction closed on June 10, 2026, announced via press release on June 12, 2026
- PRV was originally granted by the FDA in March 2026 in connection with KRESLADI approval
Financial Impact
Gross proceeds of $180.0 million added; pre-sale cash was $144.4 million, post-sale pro forma cash ~$322.6 million
Risk Factors
- Pipeline execution and clinical trial risks remain
- Stock may have already priced in the PRV sale from the prior announcement
- One-time monetization event without recurring revenue impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-024997 |
| Document: ef20076119_ex99-1.htm | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index-headers.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997.txt | 0001140361-26-024997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $3.41 $3.35 | ▼ −1.76% | ▼ −3.89% | $2.56 (−24.93%) |
Aug 20, 2026 6w ago | Insider Cluster | $3.48 $3.62 | ▲ +4.02% | ▲ +2.91% | $2.56 (−26.44%) |
Aug 17, 2026 6w ago | Insider Cluster | $3.34 $3.78 | ▲ +13.17% | ▲ +13.37% | $2.56 (−23.35%) |
Aug 13, 2026 7w ago | Insider Cluster | $3.34 $3.48 | ▲ +4.04% | ▲ +6.01% | $2.56 (−23.35%) |
Aug 10, 2026 7w ago | 8-K | $3.50 $3.34 | ▼ −4.57% | ▼ −4.17% | $2.56 (−26.86%) |
Aug 3, 2026 8w ago | 8-K | $3.41 $3.64 | ▲ +6.74% | ▲ +4.72% | $2.56 (−24.93%) |
Jun 30, 2026 13w ago | 8-K | $3.52 $4.07 | ▲ +15.63% | ▲ +15.36% | $2.56 (−27.27%) |
Jun 12, 2026 16w ago | 8-K | $2.75 $3.35 | ▲ +21.82% | ▲ +21.15% | $2.56 (−6.91%) |
May 26, 2026 18w ago | Insider Cluster | $2.99 $2.92 | ▼ −2.34% | ▼ −2.81% | $2.56 (−14.38%) |
May 7, 2026 21w ago | Insider Cluster | $3.25 $2.96 | ▼ −8.92% | ▼ −9.89% | $2.56 (−21.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access